Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced
Non–Small-Cell Lung Cancer: Results of th Page 1 Pemetrexed Versus Pemetrexed and …

Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in
chemonaive patients with locally advanced or metastatic non–small cell lung cancer …

Abstract On September 26, 2008, the US Food and Drug Administration approved
pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for use in …

Objective Pemetrexed has been approved for second-line treatment in non-small cell lung
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …

7506 Background: No standard of care exists for patients with advanced NSCLC and PS 2
and clinical practice ranges from supportive care to combination chemotherapy. Methods: In …

Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthetase and other
folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin …

Objectives Two phase III trials of advanced NSCLC patients were compared to examine
relative efficacy and safety of differing treatment regimens. The JMDB trial investigated first …

Over the past decade many large randomized trials have been conducted in patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC); however, no single …